C R Bard Inc  

(Public, NYSE:BCR)   Watch this stock  
Find more results for C. R. Bard, Inc.�
223.73
-0.52 (-0.23%)
Jul 29 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 223.07 - 225.00
52 week 172.21 - 239.43
Open 223.86
Vol / Avg. 557,852.00/480,438.00
Mkt cap 16.40B
P/E 44.19
Div/yield 0.26/0.46
EPS 5.06
Shares 73.45M
Beta 0.65
Inst. own 92%
Oct 20, 2016
Q3 2016 C R Bard Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 26, 2016
Q2 2016 C R Bard Inc Earnings Call - Webcast
Jul 26, 2016
Q2 2016 C R Bard Inc Earnings Release
May 23, 2016
C. R. Bard, Inc. 2016 Investor Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 17.09% 3.96%
Operating margin 23.48% 11.63%
EBITD margin - 30.48%
Return on average assets 12.24% 2.70%
Return on average equity 41.15% 8.19%
Employees 14,900 -
CDP Score - -

Address

730 Central Ave
NEW PROVIDENCE, NJ 07974-1139
United States - Map
+1-908-2778000 (Phone)
+1-908-2778412 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. It operates through the manufacturing and sale of medical devices segment. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD), end-stage renal disease (ESRD) and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs.

Officers and directors

Timothy M. Ring Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John H. Weiland President, Chief Operating Officer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jim C. Beasley Group President
Age: 52
Bio & Compensation  - Reuters
Timothy P. Collins Group President
Age: 55
Bio & Compensation  - Reuters
John P. Groetelaars Group President
Age: 49
Bio & Compensation  - Reuters
Christopher S. Holland Chief Financial Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Samrat S. Khichi Senior Vice President, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
John A. DeFord Ph.D. Senior Vice President - Science, Technology and Clinical Affairs
Age: 54
Bio & Compensation  - Reuters
Frank Lupisella Jr. Vice President, Controller
Age: 55
Bio & Compensation  - Reuters
Betty D. Larson Vice President - Human Resources
Age: 40
Bio & Compensation  - Reuters